270 related articles for article (PubMed ID: 8463111)
1. A cost-effectiveness analysis of hepatitis B vaccine in predialysis patients.
Oddone EZ; Cowper PA; Hamilton JD; Feussner JR
Health Serv Res; 1993 Apr; 28(1):97-121. PubMed ID: 8463111
[TBL] [Abstract][Full Text] [Related]
2. Cost effectiveness of hepatitis B vaccination strategies in Ireland: an economic evaluation.
Tilson L; Thornton L; O'Flanagan D; Johnson H; Barry M
Eur J Public Health; 2008 Jun; 18(3):275-82. PubMed ID: 18160389
[TBL] [Abstract][Full Text] [Related]
3. Probabilistic cost-effectiveness analysis of the long-term effect of universal hepatitis B vaccination: an experience from Taiwan with high hepatitis B virus infection and Hepatitis B e Antigen positive prevalence.
Hung HF; Chen TH
Vaccine; 2009 Nov; 27(48):6770-6. PubMed ID: 19735755
[TBL] [Abstract][Full Text] [Related]
4. The cost-effectiveness of introducing hepatitis B vaccine into infant immunization services in Mozambique.
Griffiths UK; Hutton G; Das Dores Pascoal E
Health Policy Plan; 2005 Jan; 20(1):50-9. PubMed ID: 15689430
[TBL] [Abstract][Full Text] [Related]
5. Cost effectiveness of hepatitis B vaccination at HIV counseling and testing sites.
Kim SY; Billah K; Lieu TA; Weinstein MC
Am J Prev Med; 2006 Jun; 30(6):498-506. PubMed ID: 16704944
[TBL] [Abstract][Full Text] [Related]
6. An economic evaluation of universal infant vaccination strategies against hepatitis B in Thailand: an analytic decision approach to cost-effectiveness.
Vimolket T; Poovorawan Y
Southeast Asian J Trop Med Public Health; 2005 May; 36(3):693-9. PubMed ID: 16124440
[TBL] [Abstract][Full Text] [Related]
7. Improved hepatitis B vaccination rates in ESRD patients in California.
Brown J; Peters V
Adv Ren Replace Ther; 2000 Oct; 7(4 Suppl 1):S95-9. PubMed ID: 11053594
[TBL] [Abstract][Full Text] [Related]
8. [Analysis on economic efficacy regarding previous strategies and current recommendations for vaccination against hepatitis B virus in China].
Zhang SX; Dang RB; Zhang WD; Liang XF; Cui FQ
Zhonghua Liu Xing Bing Xue Za Zhi; 2008 Oct; 29(10):1003-8. PubMed ID: 19173882
[TBL] [Abstract][Full Text] [Related]
9. Effects of oral levamisole as an adjuvant to hepatitis B vaccine in adults with end-stage renal disease: a meta-analysis of controlled clinical trials.
Alavian SM; Tabatabaei SV
Clin Ther; 2010 Jan; 32(1):1-10. PubMed ID: 20171406
[TBL] [Abstract][Full Text] [Related]
10. [Study on the cost-effectiveness, benefit and utility analysis on the infant inoculation hepatitis B vaccine in Shanghai].
Wu GY; Gong YL; Yu SL; Shao RT; Qin HJ
Zhonghua Liu Xing Bing Xue Za Zhi; 2004 Jun; 25(6):474-8. PubMed ID: 15231120
[TBL] [Abstract][Full Text] [Related]
11. Incidence of HAV and HBV infections and vaccination rates in patients with autoimmune liver diseases.
Wörns MA; Teufel A; Kanzler S; Shrestha A; Victor A; Otto G; Lohse AW; Galle PR; Höhler T
Am J Gastroenterol; 2008 Jan; 103(1):138-46. PubMed ID: 17970833
[TBL] [Abstract][Full Text] [Related]
12. Pertussis in adolescents and adults: should we vaccinate?
Lee GM; Lebaron C; Murphy TV; Lett S; Schauer S; Lieu TA
Pediatrics; 2005 Jun; 115(6):1675-84. PubMed ID: 15930232
[TBL] [Abstract][Full Text] [Related]
13. [Cost-benefits of vaccination against hepatitis B in hospital personnel in Venezuela].
Fernández Barboza R; Rivero D; Echeverría B; Machado IV
Bol Oficina Sanit Panam; 1991 Jul; 111(1):16-23. PubMed ID: 1834080
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of conjugate meningococcal vaccination strategies in the United States.
Shepard CW; Ortega-Sanchez IR; Scott RD; Rosenstein NE;
Pediatrics; 2005 May; 115(5):1220-32. PubMed ID: 15867028
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness analysis of hepatitis A vaccination strategies for adults.
O'Connor JB; Imperiale TF; Singer ME
Hepatology; 1999 Oct; 30(4):1077-81. PubMed ID: 10498662
[TBL] [Abstract][Full Text] [Related]
16. [Cost-benefit analysis of vaccinal prevention of hepatitis B policy].
Kerleau M; Flori YA; Nalpas B; Lanoé JL; Berthelot P; Fardeau-Gautier M
Rev Epidemiol Sante Publique; 1995; 43(1):48-60. PubMed ID: 7892516
[TBL] [Abstract][Full Text] [Related]
17. Indications for use of hepatitis B vaccine, based on cost-effectiveness analysis.
Mulley AG; Silverstein MD; Dienstag JL
N Engl J Med; 1982 Sep; 307(11):644-52. PubMed ID: 6810170
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of hepatitis B vaccination using HEPLISAV™ in selected adult populations compared to Engerix-B® vaccine.
Kuan RK; Janssen R; Heyward W; Bennett S; Nordyke R
Vaccine; 2013 Aug; 31(37):4024-32. PubMed ID: 23707166
[TBL] [Abstract][Full Text] [Related]
19. [A cost-effectiveness analysis of vaccination against the hepatitis B virus].
Antoñanzas F; Forcén T; Garuz R
Med Clin (Barc); 1992 Jun; 99(2):41-6. PubMed ID: 1630178
[TBL] [Abstract][Full Text] [Related]
20. [Cost-effectiveness analysis of different alternatives of universal vaccination against hepatitis B in the region of Murcia].
Guillén Grima F; Espín Ríos MI
Med Clin (Barc); 1995 Feb; 104(4):130-6. PubMed ID: 7898156
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
